Stay updated on Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial

Sign up to get notified when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an update or modification related to the efficacy or tolerability evaluation of brentuximab vedotin in the treatment of Hodgkin lymphoma and peripheral T-cell lymphoma in older patients or those with significant comorbidities.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:16.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change includes examples of eligibility criteria such as a person's general health condition or prior treatments.
    Difference
    18%
    Check dated 2024-05-22T21:13:20.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:28:02.000Z thumbnail image

Stay in the know with updates to Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.